HIV and Messenger RNA (mRNA) Vaccine.
HIV and Messenger RNA (mRNA) Vaccine.
复制标题
DOI：
10.7759/cureus.16197
复制
发表时间：
2021-07
期刊：
影响因子：
--
通讯作者：
Jean-Charles G
中科院分区：
文献类型：
--
作者：
Khalid K;Padda J;Khedr A;Ismail D;Zubair U;Al-Ewaidat OA;Padda S;Cooper AC;Jean-Charles G
人类免疫缺陷病毒（HIV）是逆转录病毒科慢病毒属的一部分，通过一系列复杂的步骤将其基因组整合到宿主DNA中。HIV可分为两种类型，HIV-1型（HIV-1）和HIV-2型（HIV-2），其中HIV-1型是世界上最常见的类型。自该流行病开始以来，已有7 600万人感染，死亡人数为3 300万人。即使在40年后，也没有找到治疗这种大流行病的方法。mRNA疫苗的发展导致进一步研究mRNA疫苗在艾滋病毒中的应用，试图创造一种预防性和治疗性的治疗方法。虽然信使RNA （mRNA）疫苗已经存在多年，但由于其在未预见的冠状病毒大流行中的作用和反应，最近引起了人们的关注。mRNA疫苗面临着诸多挑战，但与传统疫苗相比，它也具有许多优势，如安全性、有效性、快速制备和多功能性。mRNA疫苗已显示出良好的效果，具有巨大的潜力。在这篇综述中，我们讨论了mRNA疫苗的类型、开发、交付、优势、挑战以及我们如何努力克服这些挑战。
Human immunodeficiency virus (HIV) is a part of the lentivirus genus of the retroviridae family that incorporates its genome into the host DNA via a series of complex steps. HIV can be classified into two types, HIV-type 1 (HIV-1) and HIV-type 2 (HIV-2), with HIV-1 being the most common type worldwide. Seventy-six million people have been infected since the start of the pandemic, with a mortality rate of 33 million. Even after 40 years, no cure has been developed for this pandemic. The development of the mRNA vaccine has led to further research for the utilization of mRNA vaccine in HIV, in attempts to create a prophylactic and therapeutic treatment. Although messenger RNA (mRNA) vaccine has been around for many years, it has recently drawn attention due to its role and response in the unforeseen coronavirus pandemic. mRNA vaccine has faced its fair-share of challenges, but it also offers many advantages compared to conventional vaccines such as safety, efficacy, rapid preparation, and versatility. mRNA vaccine has shown promising results and has great potential. In this review, we discuss the types of mRNA vaccine, along with development, delivery, advantages, challenges, and how we are working to overcome these challenges.
登录
查看更多内容
用编码HIV-1 GAG和NEF的mRNA转染的自体树突状细胞的HIV-1感染者免疫接种：一项随机，安慰剂对照的临床试验的结果。
DOI：
10.1097/qai.0000000000000852
发表时间：
2016-03-01
期刊：
Journal of acquired immune deficiency syndromes (1999)
影响因子：
--
作者：
Gandhi RT;Kwon DS;Macklin EA;Shopis JR;McLean AP;McBrine N;Flynn T;Peter L;Sbrolla A;Kaufmann DE;Porichis F;Walker BD;Bhardwaj N;Barouch DH;Kavanagh DG
通讯作者：
Kavanagh DG
影响因子：
64.8
作者：
BRENNER, S;MESELSON, M;JACOB, F
通讯作者：
JACOB, F
影响因子：
30.5
作者：
Leong, Yew Ann;Chen, Yaping;Yu, Di
通讯作者：
Yu, Di
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
影响因子：
3.8
作者：
Leal, Lorna;Guardo, Alberto C.;Garcia, Felipe
通讯作者：
Garcia, Felipe